Business Description
PhotoCure ASA
SIC : 3845
ISIN : NO0010000045
Total Employee Number:
101Compare
Compare
Traded in other countries / regions
PHO.Norway0IMT.UKPHS.GermanyPHCUF.USAPHOO.Sweden IPO Date
2000-05-29Description
Photocure ASA is a Norwegian specialty pharmaceutical company focused on photodynamic therapy and diagnosis, particularly in urology. Its lead product, hexaminolevulinate, is marketed as Hexvix in Europe and Cysview in the United States and Canada for the detection of bladder cancer during cystoscopy, where it improves visualisation of malignant lesions. The company also develops and commercialises other photodynamic technologies. Photocure generates revenue primarily through product sales and licensing or royalty arrangements with regional partners, including Ipsen in Europe and KARL STORZ in the United States, rather than through a large direct sales force. Its main markets are Europe and North America, with additional distribution in selected other territories. The company is headquartered in Oslo and is listed on the Oslo Stock Exchange.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 15.7 | |||||
Equity-to-Asset | 0.67 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | 0.06 | |||||
Interest Coverage | 2.66 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 4.59 | |||||
Beneish M-Score | -1.72 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 11.3 | |||||
3-Year EPS without NRI Growth Rate | 71.7 | |||||
3-Year Book Growth Rate | 2.2 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 9.61 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 26.7 | |||||
9-Day RSI | 29.17 | |||||
14-Day RSI | 33.35 | |||||
3-1 Month Momentum % | 0.18 | |||||
6-1 Month Momentum % | -19.58 | |||||
12-1 Month Momentum % | -7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.65 | |||||
Quick Ratio | 3.11 | |||||
Cash Ratio | 1.6 | |||||
Days Inventory | 353.59 | |||||
Days Sales Outstanding | 58.79 | |||||
Days Payable | 194.25 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 0.6 | |||||
Shareholder Yield % | 1.15 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 93.59 | |||||
Operating Margin % | 16.01 | |||||
Net Margin % | 11.6 | |||||
EBITDA Margin % | 24.84 | |||||
FCF Margin % | 11.28 | |||||
OCF Margin % | 15.82 | |||||
ROE % | 14.94 | |||||
ROA % | 10.43 | |||||
ROIC % | 16.93 | |||||
3-Year ROIIC % | 9520.52 | |||||
ROC (Joel Greenblatt) % | 137.33 | |||||
ROCE % | 21.01 | |||||
Years of Profitability over Past 10-Year | 3 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 16.74 | |||||
Forward PE Ratio | 16 | |||||
PE Ratio without NRI | 16.74 | |||||
Price-to-Owner-Earnings | 30.91 | |||||
PS Ratio | 1.88 | |||||
PB Ratio | 2.19 | |||||
Price-to-Tangible-Book | 5.5 | |||||
Price-to-Free-Cash-Flow | 18.26 | |||||
Price-to-Operating-Cash-Flow | 13.07 | |||||
EV-to-EBIT | 8.41 | |||||
EV-to-EBITDA | 6.93 | |||||
EV-to-Forward-EBITDA | 91.91 | |||||
EV-to-Revenue | 1.72 | |||||
EV-to-Forward-Revenue | 13.31 | |||||
EV-to-FCF | 18.19 | |||||
Price-to-GF-Value | 0.73 | |||||
Price-to-Projected-FCF | 1.28 | |||||
Price-to-Median-PS-Value | 0.38 | |||||
Price-to-Graham-Number | 2.02 | |||||
| Price-to-Net-Current-Asset-Value | 17.63 | |||||
Earnings Yield (Greenblatt) % | 11.88 | |||||
FCF Yield % | 4.63 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
PhotoCure ASA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 678.716 | ||
| EPS (TTM) (kr) | 2.94 | ||
| Beta | -0.3776 | ||
| 3-Year Sharpe Ratio | 0.22 | ||
| 3-Year Sortino Ratio | 0.37 | ||
| Volatility % | 36.09 | ||
| 14-Day RSI | 33.35 | ||
| 14-Day ATR (kr) | 0.454871 | ||
| 20-Day SMA (kr) | 54.185 | ||
| 12-1 Month Momentum % | -7 | ||
| 52-Week Range (kr) | 50.8 - 78.3 | ||
| Shares Outstanding (Mil) | 26.92 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
PhotoCure ASA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
PhotoCure ASA Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-18 14:00 | In 150 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-18 07:00 | In 150 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-28 | In 36 days | ||
| Third quarter earnings results for 2026 | 2026-10-28 | In 36 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-29 14:00 | -- | ||
| Second quarter earnings results for 2026 | 2026-07-29 08:00 | -- | ||
| General meeting for 2025 | 2026-06-26 17:00 | -- | ||
| First quarter earnings conference call for 2026 | 2026-05-07 14:00 | -- | ||
| First quarter earnings results for 2026 | 2026-05-07 | -- | ||
| Annual report for 2025 | 2026-04-27 | -- |
Show
Entries
PhotoCure ASA Frequently Asked Questions
What is PhotoCure ASA(OSTO:PHOO)'s stock price today?
The current price of OSTO:PHOO is kr52.00. The 52 week high of OSTO:PHOO is kr78.30 and 52 week low is kr50.80.
When is next earnings date of PhotoCure ASA(OSTO:PHOO)?
The next earnings date of PhotoCure ASA(OSTO:PHOO) is 2026-10-28.
Does PhotoCure ASA(OSTO:PHOO) pay dividends? If so, how much?
PhotoCure ASA(OSTO:PHOO) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers